Thrombotic thrombocytopenic purpura following administration of the Moderna booster vaccine

BMJ Case Rep. 2022 Mar 24;15(3):e247576. doi: 10.1136/bcr-2021-247576.

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a type of thrombotic microangiopathy that is characterized by microangiopathic haemolytic anaemia, consumption thrombocytopenia and organ injury. It is caused by a severe deficiency of ADAMTS13, which can be either congenital or acquired. There is a plethora of things that can cause the acquired form, including medications and infections. Vaccines have also been shown to cause TTP. In the midst of the COVID-19 pandemic, with multiple new vaccines being developed and distributed to the masses, the medical community needs to be aware of adverse events associated with these new vaccines. We present a case of TTP following administration of the Moderna booster vaccine.

Keywords: COVID-19; haematology (incl blood transfusion); immunological products and vaccines; malignant and benign haematology.

Publication types

  • Case Reports

MeSH terms

  • Anemia, Hemolytic* / complications
  • COVID-19* / prevention & control
  • Humans
  • Immunization, Secondary / adverse effects
  • Pandemics
  • Purpura, Thrombotic Thrombocytopenic* / chemically induced
  • Purpura, Thrombotic Thrombocytopenic* / complications